RESTYLANE REFYNE PP
Generic Name and Formulations:
Hyaluronic acid 20mg/mL, lidocaine 3mg/mL; injectable gel implant.
Galderma Laboratories, Inc.
Indications for RESTYLANE REFYNE:
Correction of moderate-to-severe facial wrinkles and folds (eg, nasolabial folds).
See full labeling. Inject slowly into the mid-to-deep dermis with least amount of pressure necessary. May use supplementary anesthesia during and post-inj. >21yrs: Individualize. Initial treatment: usually 1.5mL per site; repeat treatment: usually 1mL per site. May require touch-up treatments to achieve desired effects.
History of anaphylaxis or presence of multiple severe allergies. Allergies to Gram (+) bacterial proteins.
Should only be used by trained and experienced healthcare practitioners. Obtain patient's complete medical history prior to initiation. Avoid intravascular inj; discontinue immediately if changes in vision, signs of stroke, blanching of skin or unusual pain during or shortly after procedure occurs. Avoid sites with permanent implant. Risk of infection. Defer if active inflammatory process, infection or tumor is present at specific sites. Use in non-facial areas: not established. Possible risk of an inflammatory reaction at implant site if laser treatment, chemical peeling, or any other procedure based on active dermal response is considered after Restylane Refyne or if product is given before skin has healed completely after such a procedure. Bleeding disorders. Risk of herpes reactivation in patients with a history of herpetic eruption. Advise patients to avoid strenuous exercise and extensive sun or heat exposure within first 24hrs. Patients (<22yrs), pregnancy, nursing mothers: not established.
Caution with concomitant immunosuppressants. Increased bruising or bleeding at inj sites with concomitant aspirin, NSAIDs, warfarin.
Inj site reactions (eg, redness, swelling, bruising, lump/bump formation, pain/tenderness, itching).
Single-use syringe—1 (w. needles)
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|